Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeting Taspase1 for Cancer Therapy—Response

Targeting Taspase1 for Cancer Therapy—Response Targeting Taspase1 for Cancer Therapy—Response var callbackToken='5058BFADFEAB7CA'; Skip to main page content Home OnlineFirst Current Issue Past Issues Subscriptions Alerts Feedback AACR Publications AACR Home Search GO Advanced Search Institution: DeepDyve User Name Password Sign In Targeting Taspase1 for Cancer Therapy—Response David Y. Chen 1 , Shugaku Takeda 2 , Toshinao Oyama 2 , and James J. Hsieh 2 Authors' Affiliations: 1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; and 2 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York Corresponding Author: James J. Hsieh, Memorial Sloan-Kettering Cancer Center, 415 E. 68 th Street, Z801, New York, NY10065. Phone: 646-888-3263; Fax: 646-888-3266; E-mail: hsiehj@mskcc.org We appreciate the interests of Stauber and colleagues in our study, identifying a small-molecule Taspase1 inhibitor (TASPIN) NSC48300 that disrupts cancer cell growth ( 1 ). First, regarding the expression level of Taspase1 in 293T cells, Taspase1 was first purified from 293T cells on the basis of the presence of potent proteolytic activity ( 2 ). Therefore, the claim that 293T has no measurable expression of Taspase1 is incorrect. The activity of Taspase1 in 293T cells is quite evident as the dual fluorescent proteolytic reporter (GFP 2XNES-MLL(2500-2900)-3XNLS dsRED2) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

Targeting Taspase1 for Cancer Therapy—Response

Targeting Taspase1 for Cancer Therapy—Response

Cancer Research , Volume 72 (11): 2913 – Jun 1, 2012

Abstract

Targeting Taspase1 for Cancer Therapy—Response var callbackToken='5058BFADFEAB7CA'; Skip to main page content Home OnlineFirst Current Issue Past Issues Subscriptions Alerts Feedback AACR Publications AACR Home Search GO Advanced Search Institution: DeepDyve User Name Password Sign In Targeting Taspase1 for Cancer Therapy—Response David Y. Chen 1 , Shugaku Takeda 2 , Toshinao Oyama 2 , and James J. Hsieh 2 Authors' Affiliations: 1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; and 2 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York Corresponding Author: James J. Hsieh, Memorial Sloan-Kettering Cancer Center, 415 E. 68 th Street, Z801, New York, NY10065. Phone: 646-888-3263; Fax: 646-888-3266; E-mail: hsiehj@mskcc.org We appreciate the interests of Stauber and colleagues in our study, identifying a small-molecule Taspase1 inhibitor (TASPIN) NSC48300 that disrupts cancer cell growth ( 1 ). First, regarding the expression level of Taspase1 in 293T cells, Taspase1 was first purified from 293T cells on the basis of the presence of potent proteolytic activity ( 2 ). Therefore, the claim that 293T has no measurable expression of Taspase1 is incorrect. The activity of Taspase1 in 293T cells is quite evident as the dual fluorescent proteolytic reporter (GFP 2XNES-MLL(2500-2900)-3XNLS dsRED2)

Loading next page...
 
/lp/american-association-of-cancer-research/targeting-taspase1-for-cancer-therapy-response-0KHxX4Iu02

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 2012 American Association for Cancer Research
ISSN
0008-5472
eISSN
1538-7445
DOI
10.1158/0008-5472.CAN-12-1074
Publisher site
See Article on Publisher Site

Abstract

Targeting Taspase1 for Cancer Therapy—Response var callbackToken='5058BFADFEAB7CA'; Skip to main page content Home OnlineFirst Current Issue Past Issues Subscriptions Alerts Feedback AACR Publications AACR Home Search GO Advanced Search Institution: DeepDyve User Name Password Sign In Targeting Taspase1 for Cancer Therapy—Response David Y. Chen 1 , Shugaku Takeda 2 , Toshinao Oyama 2 , and James J. Hsieh 2 Authors' Affiliations: 1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; and 2 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York Corresponding Author: James J. Hsieh, Memorial Sloan-Kettering Cancer Center, 415 E. 68 th Street, Z801, New York, NY10065. Phone: 646-888-3263; Fax: 646-888-3266; E-mail: hsiehj@mskcc.org We appreciate the interests of Stauber and colleagues in our study, identifying a small-molecule Taspase1 inhibitor (TASPIN) NSC48300 that disrupts cancer cell growth ( 1 ). First, regarding the expression level of Taspase1 in 293T cells, Taspase1 was first purified from 293T cells on the basis of the presence of potent proteolytic activity ( 2 ). Therefore, the claim that 293T has no measurable expression of Taspase1 is incorrect. The activity of Taspase1 in 293T cells is quite evident as the dual fluorescent proteolytic reporter (GFP 2XNES-MLL(2500-2900)-3XNLS dsRED2)

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Jun 1, 2012

There are no references for this article.